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Abstract: Vascular endothelial growth factor (VEGF) is an important angiogenic factor in the female reproductive tract. It
binds to cell surface through ligand-stimulatable tyrosine kinase receptors, the most important being VEGFR-1 (flt-1) and
VEGFR-2 (flk-1). The broad ligament of the uterus is a dynamic organ consisting of specialized complexes of blood vessels
connected functionally to the uterus, oviduct and ovary. Endothelial cells form an inner coating of the vessel walls and thus
they stay under the influence of various modulators circulating in blood including ovarian steriods involved in developmental
changes in the female reproductive system. The aim of the present study was to immunolocalize VEGF and its two receptors:
VEGFR-1 and VEGFR-2 in the broad ligament of the uterus in the area of vascular subovarian plexus during different phases
of the estrous cycle in pig and to determine the correlation between immunoreactivity of the investigated factors and phases
of the estrous cycle. The study was performed on cryostat sections of vascular subovarian plexus stained immunohistochemically
by ABC method. Specific polyclonal antibodies: anti-VEGF, anti-VEGFR-1 and anti-VEGFR-2 were used. Data were subjected to
one-way analysis of variance. Our study revealed the presence of VEGF and its receptors in endothelial and smooth muscle cells of
VSP arteries. All agents displayed phase-related differences in immunoreactivity suggesting the modulatory effect of VEGF,
VEGFR-1 and VEGFR-2 on the arteries of the VSP in the porcine broad ligament of the uterus. (www.cm-uj.krakow.pl/FHC)
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Introduction
Since VEGF was first discovered in 1983 by Harold F.
Dvorak and coworkers, a great majority of investiga-
tions have been conducted and many studies have de-
scribed the role of this factor, its localization,
modulatory effects and influence of other angiogenic
and non-angiogenic factors as well as hormones that
may regulate its expression [9, 15, 24, 25, 32, 34, 46, 52,
54, 56, 57, 58]. 
VEGF in the reproductive tract was first described in
the uterus of the mouse, then human, rat, ewe, rabbit and
monkey [6, 10 , 14, 41]. Vascular endothelial growth
factor/vascular permeability factor (VEGF/VPF) is an
endothelial-cell-specific mitogen and thus, a prime regu-
lator of vascular formation and function promoting mi-
gration of ECs (endothelial cells) and the formation of
new vessels, regulating their permeability, inducing vas-
cular leakage and fenestrations in ECs of small venules
and capillaries [6, 44]. It is a basic, heparin-binding,
homodimeric glycoprotein of 45 kD secreted by various
tissues and cells such as: macrophages, glandular, epi-
thelial, stromal, glial, tumor, smooth muscle cells, kerati-
nocytes and ovarian cysts [47]. VEGF also regulates
vascular tone, production of vasoactive molecules: von
Willebrand factor, nitric oxide, cytokines [5, 24, 33, 49]
and recruits progenitor endothelial cells from the bone
marrow [8]. It has been found to be a key regulator of
angiogenesis and vasculogenesis during early embryonic
development [4, 20] and in early postnatal life [13].
Production of VEGF is regulated by several mechan-
isms: hypoxia [15, 50, 52], PDGF, EGF, TGF-β, steroid
hormones, deregulated glucose values [53], cell dif-
ferentiation, oncogenes [46] but all of these need further
detailed investigations.
The VEGF family consists of several members:
VEGF-A, VEGF-B, VEGF-C, VEGF-D, PLGF -
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placental growth factors and VEGF-E [22, 26, 29, 31,
38]. VEGF-A is best known and described as a major
regulator of normal and abnormal angiogenesis [11,
12]. Several isoforms of VEGF were discovered. In-
itially, there were four variants. They consisted of
121, 165, 189 and 206 amino acids of almost indenti-
cal biological activities [16]. Nowadays, it is proven
that more isoforms are generated including VEGF 183
[21] and VEGF 145 [40].
VEGF is a multifunctional factor. Its biological ef-
fects are mediated by two main tyrosine kinase recep-
tors: VEGFR-1 and VEGRF-2 expressing different roles
in vivo and thus responsible for functional variety of
VEGF activities [8, 43, 45, 47, 57, 58]. Both receptors
after ligand-induced dimerization activate intracellular
signaling casades leading to their autophosphorylation
[55, 56]. Activated receptor kinase answers in a bio-
chemical and physiological fashion to stimulate DNA
synthesis and determine the cellular response. However,
VEGFR-2 reveals strong ligand-dependent tyrosine
phosphorylation, whereas the response of VEGFR-1 is
weak [56, 59].
Vascular endothelial growth factor is expressed at
high levels in various normal male and female tissues [2,
36] as a regulatory factor participating in mammalian
reproduction. Both, VEGF and its receptors are sug-
gested to be influenced by ovarian steroids involved in
developmental changes and functional activity in female
reproductive tract [7, 14, 18, 19, 30, 32, 37, 51].
To gain a better understanding of the VEGF and its
receptors expression in the broad ligament of the ute-
rus - dynamic tissue, responding to steroid hormones
and locally produced growth factors and cytokines
throughout the cycle - our study was aimed at the de-
tailed cellular localization of these agents. 
This study is based on the hypothesis that during a
normal reproductive cycle, levels of VEGF and its re-
ceptors in the endothelium and smooth muscle cells of
VSP arteries might fluctuate and might be dependent on
different stages of the cycle. Current studies charac-
terized VEGF in terms of its role in vascular biology but
many conclusions remain unclear with regard to hor-
monal regulation. Thus, it seemed to be important to
examine VEGF and its receptors localization and ex-
pression in the area of dynamic hormonal influence -
VSP of the broad ligament of the uterus.
Materials and methods
Animals and tissue preparation. The study was performed on 16
cyclic pigs in the following phases of the estrous cycle: follicular
(17-21) n=4, early luteal (1-5) n=4, mid luteal (6-12) n=4 and late
luteal (13-16) n=4. Tissues of vascular subovarian plexus (VSP) were
excised below the ovary and then fixed in 4% paraformaldehyde
(PFA) in 0.1M phosphate buffer (PB, pH=7.4). After several washes
in 0.1M PB, all tissue samples were stored in 18% sucrose for
cryoprotection. Ten μm cryostat sections were mounted on ge-
latin/chrome-alum-coated slides. Next, sections were stained immu-
nohistochemically for VEGF, VEGFR-1 and VEGFR-2 activity.
Immunostaining for VEGF, VEGFR-1 and VEGFR-2. Immunos-
taining was done on consecutive sections (3 per uterus). In order to
block endogenous peroxidase, sections were treated with hydrogen
peroxide in methanol, washed in 0.1M PBS (phosphate buffer saline,
pH=7.4), treated with glycine to block the activity of aldehyde groups
and then blocked with 10% normal goat serum (NGS) for 1 h at room
temperature. Next, sections were incubated overnight at room tem-
perature with primary rabbit polyclonal antibodies: anti-VEGF
(A:20, sc-152) in dilution 1:200, anti-VEGFR-1 (c-17, sc-316) in
dilution 1:150, anti-VEGFR-2 (N-931, sc-505) in dilution 1:100
(Santa Cruz Biotechnology, Inc.). After overnight incubation with
these antibodies, sections were washed in PBS and incubated again
with anti-rabbit biotynylated IgG (Vectastatin ABC Kit) diluted
1:400 for 1 h. The following incubation with avidin-biotin-peroxi-
dase complex (ABC Reagent, Vectastatin Kit) lasted 45 min at room
temperature. The reaction was visualized by incubating sections in
0.3 mg/ml 3,3‘-diaminobenzidine tetrahydrochloride (DAB) and
0.01% hydrogen peroxide in PBS. Finally, sections were dehydrated
and cover-slipped with DePeX. Negative controls were incubated
with 10% NGS instead of the primary, secondary or both antibodies.
The intensity of immunostaining was estimated by measuring the
optical density using Olympus DP Soft. Optical density is the method
of measuring the intensity of visible products of tissue staining. The
measured values range from 0 to 250 where 0 means black and 250
white colour. When the of immunostaining is strong the values are
close to 0. However, all data in this study are presented as absolute
values, so the stronger is tissue reaction the higher is the value of
optical density. 20 pixel values were measured in the endothelium
and muscular layer of each from 21 chosen arteries (7 from each
section). That gave 1680 measurements per phase (420 measure-
ments/uterus) for endothelium and the same for muscular layer. The
data was subjected to one-way analysis of variance (Statistica 5,0).
Differences among phases were tested by Tukey‘s test. All values
were expressed as means (±SEM). 
Results
Light microscopic analysis of the sections revealed es-
trous phase-related differences in expression of VEGF,
VEGFR-1 and VEGFR-2 through the examined stages
of the estrous cycle. The positive immunostaining was
found in endothelial and smooth muscle cells of the
arteries in the area of VSP. 
Endothelial cells
Quantitative evaluation of the optical density of the
VEGF, VEGFR-1 and VEGFR-2 immunoreactivity re-
vealed their significant variability depending on the
estrous cycle. The highest immunoreactivity of VEGF
was displayed during the follicular phase of the estrous
cycle (Figs. 1A, 2A) (P≤0.001). The intensity of staining
decreased significantly during early luteal phase (Figs.
1B, 2A) to increase again during mid luteal phase (Figs.
1C, 2A). The weakest staining for VEGF was detected
during early luteal phase and it did not significantly
differ from the VEGF expression during late luteal phase
(Figs. 1D, 2A) of the estrous cycle.
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Comparing results for VEGF with those obtained for
VEGFR-1, we found that the receptor‘s signal during the
follicular phase was the most intense (Figs. 1E, 3A) and
at the similar level as VEGF. In contrast to VEGF,
VEGFR-1 displayed strong immunoreactivity in the
early luteal phase (Figs. 1F, 3A). In the mid luteal phase
(Figs. 1G, 3A), the immunostaining was the weakest.
Figures 1I-L present the immunoreactivity of
VEGFR-2 in arterial endothelial cells. The strongest
immunostaining was observed during the follicular
phase of the estrous cycle (Figs. 1I, 4A), similarly to
VEGF and VEGFR-1, although the differences between
all phases were generally weak and displayed less sig-
nificance.
Fig. 1. Representative micrographs presenting the VEGF, VEGFR-1 and VEGFR-2 immunolocalization in the endothelial cells (arrowheads)
and in the muscular layer (asterisks) of arterial vessels in the area of vascular subovarian plexus (VSP) of uterine broad ligament during the
follicular (A, E, I), early luteal (B, F, J), mid luteal (C, G, K) and late luteal (D, H, L) phases of the estrous cycle in pig. Scale bar: 100 μm.
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Muscular layer
Immunostaining for all the examined factors in the mus-
cular layer of VSP arteries was definitely weaker but
optically visible through all the studied stages. VEGF
displayed the strongest immunoreactivity during the
follicular phase (Figs. 1A, 2B) and it was significantly
different from other stages of the estrous cycle. The
weakest immunoreaction for VEGF was observed dur-
ing early luteal phase (Figs. 1B, 2B). This result corre-
sponds with VEGFR-1 immunoreactivity because this
receptor showed also the weakest reaction during early
luteal phase (Figs. 1F, 3B), whereas the strongest immu-
nostaining was displayed during mid luteal phase (Figs.
1G, 3B). The immunostaining revealed by VEGFR-2
during follicular, early luteal and late luteal phases (Figs.
1I, J, L, 4B) was almost identical if expressed as values,
while the staining in the mid luteal phase was weaker
and significantly different from the other three.
Taken together, VEGF and both receptors displayed
the strongest immunoreactivity in the follicular phase in
endothelial cells, whereas in the smooth muscle cells
only the pattern of VEGF immunostaining was similar.
In all secretory phases, the immunoreactivity of VEGF
and its receptors were different for endothelial and
smooth muscle cells. The probable explanation is that
they play different roles in the endothelium and muscu-
lar layer. Most biological functions of VEGF are medi-
ated via VEGFR-2 and the role of VEGFR-1 is currently
still to be discovered. 
Discussion
This study presents the cellular localization of VEGF,
VEGFR-1 and VEGFR-2 in the porcine broad ligament
of the uterus. We have demonstrated the presence of
these factors in the endothelial cells and muscular layer
of the arteries of vascular subovarian plexus during the
estrous cycle suggesting that their immunohistochemi-
cal response might be phase-related. Expression of
VEGF, VEGFR-1 and VEGFR-2 in the reproductive
vascular system still remains poorly understood, al-
though it is proven that these factors play a crucial role
in the female reproductive tract. Our study was focused
on the uterine broad ligament vasculature supplying all
reproductive organs with blood, oxygen, vasoactive
molecules, hormones and other active substances. There
is no data in the literature describing similar studies.
Most of papers refer to reproductive organs: ovary and
uterus of various animals and of humans [3, 23, 28, 30,
32, 42, 57] and these organs are particularly interesting
in terms of VEGF localization and steroid hormones
influencing this growth factor. Cooper and coworkers
[9] described localization of VEGF and VEGFR-1 in
human placenta and decidua. VEGF immunoreactivity
was localized to placental macrophages and glandular
epithelium and also maternal macrophages in decidua.
The immunostaining of VEGFR-1 was observed in
extravillous trophoblast. In human endometrium immu-
noreactivity of VEGF in glandular and stromal cells was
significantly higher during the proliferative phase of the
menstrual cycle [34]. The authors concluded that VEGF
expression appeared to be under the influence of estro-
gens rather than progesterone. Similar results were dem-
onstrated by Li et al. [27], who also immunolocalized
VEGF in human endometrium. They detected no stain-
ing around the endometrial blood vessels throughout the
secretory phase. The intense immunostaining was ob-
served in stromal cells in the mid to late proliferative
endometrium, which corresponds to the increase in the
estradiol concentration. Observations by Winther and
coworkers [57] confirmed the immunolocalization of
VEGF and its both receptors in uterine luminal and
glandular epithelium, trophoblast cells, endothelial cells
and, for the first time, in smooth muscle cells of the
vessel walls in pregnant and non-pregnant pigs. Endo-
thelial cells of arteries displayed intense immunostain-
ing for VEGFR-1 and VEGFR-2 during the late luteal
phase of the estrous cycle. Evidence suggests that VEGF
activity is spatially and temporally expressed during the
cycle in ovary and uterus [39]. 
There are many studies supporting regulatory in-
fluence of estrogens on VEGF mRNA expression. Cul-
linan-Bove and Koos [10] have shown that VEGF is
regulated by estradiol in the rat uterus in vivo inducing
increase in uterine capillary permeability and growth.
Ochoa et al. [37] investigated VEGF in the rat pituitary
and concluded that VEGF in the cyclic uterus are under
the control of estrogens. Reynolds et al. [42] do-
cumented rapid uterine response of VEGF to estradiol
17β in ovariectomized ewes. 
Many investigations were also conducted in vitro on
human uterine stromal cells [51], human carcinoma cell
lines [6], and in breast cancer cells [48]. Isolated human
endometrial cells treated with estradiol (E2) revealed
significant, 3.1-fold increase in VEGF mRNA express-
ion over the control value [51]. VEGF and its receptors
as estrogen-responsive factors play an important role in
endometrial angiogenesis, in the increase in microvas-
cular permeability and hormone-dependent vascular
growth. The study of Meduri et al. [32] was directed at
determining the expression and modulation of VEGFR-
1 and VEGFR-2 and at seeking their relation to the phase
of the cycle. The immunohistochemical investigation
revealed that the number of VEGFR-2-stained capil-
laries was maximal in the proliferative phase, whereas
about 2-fold higher number of VEGFR-1 stained capil-
laries was observed in the secretory phase of the men-
strual cycle. 
Immunoreactivity of VEGFR-2 was higher in the
midsecretory stage of the cycle, whereas VEGFR-1
staining was intense during the late proliferative
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phase. Malamitsi-Puchner et al. [30] demonstrated that
vascular expression of VEGFR-2 was high during
the proliferative phase. These findings, as well as
others suggest a relation of VEGF and its receptors
immunoreactivity to the phases of the reproductive
cycle.
A limited number of studies suggest that VEGF
expression is increased not only by estrogens but also by
progestins [7, 14, 17 , 25, 35], however, the effects of
progestins on expression of VEGF and both receptors is
not so clear as those of estrogens [19] because the
knowledge of this mechanism is just beginning to
Fig. 4. Comparison of the intensity (optical density) of VEGFR-2 immunostaining in the endothelium (A) and muscular layer (B) of VSP
arteries at various stages of the estrous cycle presented graphically. Different small letters indicate significant differences (P≤0.001). Each
value is the mean ± SEM.
Fig. 3. Comparison of the intensity (optical density) of VEGFR-1 immunostaining in the endothelium (A) and muscular layer (B) of VSP
arteries at various stages of the estrous cycle presented graphically. Different small letters indicate significant differences (P≤0.001). Each
value is the mean ± SEM.
Fig. 2. Comparison of the intensity (optical density) of VEGF immunostaining in the endothelium (A) and muscular layer (B) of VSP arteries
at various stages of the estrous cycle presented graphically. Different small letters indicate significant differences (P≤0.001). Each value is
the mean ± SEM. Abbreviations for figures 2-4: F - follicular, EL - early luteal, ML - mid luteal, LL - late luteal phases of the estrous cycle.
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emerge. Greb et al. [14] observed intense VEGF immu-
nostaining in the primate endometrial stroma after pro-
gestin treatment. According to Hyder and coworkers
[17], progesterone increases VEGF protein expression
in a human breast cancer cell line. Ancelin et al. [1]
showed that progesterone selectively increased VEGF
(189) expression in the human uterus.
The present study revealed that VEGF, VEGFR-1
and VEGFR-2 are expressed in the endothelial and
smooth muscle cells in the area of VSP of cyclic pigs.
We have observed a correlation between immunoreac-
tivities of VEGF and its receptors in arterial walls and
the estrous phases. Cyclic changes in expression of
VEGF and both receptors may suggest that these factors
remain under the influence of ovarian steroids. Positive
expression of VEGF, VEGFR-1 and VEGFR-2 in the
endothelial and smooth muscle cells gives evidence for
the hypothesis that they also play a role to act in non-en-
dothelial cells, stimulating different functions in the
vasculature. Such results might also suggest that VEGF
and both receptors remain under stronger influence of
estrogens than progesterone. Still, all  these results need
further detailed investigation.
This study is the first step leading to further investi-
gations that will demonstrate whether locally syn-
thesized VEGF acting via its receptors is affected by
ovarian steroid hormones and undergoes the cyclic
changes in the uterine vasculature through the estrous
cycle.
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